Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients

Journal of Supportive Oncology

Volumn 8, Issue 6, 2010, Pages 242-251

  Avritscher, Elenir B C ^a,b,c   Shih, Ya Chen T ^a,b,c   Sun, Charlotte C ^a,b,c   Gralla, Richard J ^a,b,c   Grunberg, Steven M ^a,b,c   Xu, Ying ^a,b,c   Elting, Linda S ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b North Shore Long Island Center for Advanced Medicine   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

ARTICLE; BREAST CANCER; CANCER PATIENT; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; ISOQUINOLINES; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; QUINUCLIDINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 78751470675     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suponc.2010.09.027     Document Type: Article

References (43)

1. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005;13:80-84. [15599601]
2. Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007;5:374-380. [17944146]
3. de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-1061. [9376266]
4. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al; 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98:2473-2482. [14635083]
5. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy- induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577. [14504060]
6. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a doubleblind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-124. [19135415]
7. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830. [15837996]
8. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947. [16717289]
9. Ettinger DS, Armstrong DK, Barbour S, et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Antiemesis, version 2.2010. http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf. Accessed September 20, 2010.
10. Carlson RW, McCormick B. Update: NCCN breast cancer clinical practice guidelines. J Natl Compr Cancer Netw 2005;3(suppl 1):S7-S11. [16280118]
11. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332:1-5. [7990859]
12. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-1559. [10824073]
13. Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009;17:589-594. [19037667]
14. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-1555. [16104039]
15. Centers for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price. 2008 ASP Drug Pricing Files. http://www.cms.hhs.gov/apps/ama/license.asp?file=/McrPartBDrugAvg SalesPrice/downloads/July2008ASPPricingFileby HCPCS.zip. Accessed July 18, 2008.
16. Thomson. Medstat. 1997-2002 MarketScan Health and Productivity Management Database User Guide and Data Dictionary. Ann Arbor, MI: Thomson Medstat; 2003.
17. Centers for Medicare and Medicaid Services. National Physician Fee Schedule and Relative Value. 2008 Physician Fee Schedule National Payment Amount File. http://www.cms.hhs.gov/PFSlookup/02_PFSSearch.asp. Accessed July 18, 2008.
18. National Inpatient Sample (NIS). NIS description of data elements. Healthcare Cost and Utilization Project (HCUP) databases. Rockville, MD: Agency for Healthcare Research and Quality; 2004. http://www.hcup-us.ahrq.gov/nisoverview.jsp#Data. Accessed May 16, 2010.
19. Haislip S, Gilmore J, Lenz WH, Gondesen T, Feinberg B. Theory in practice: improving patient outcomes and practice efficiency with a simple change in 5-HT3 receptor antagonist for preventing chemotherapy-induced nausea and vomiting (CINV). In: Third Annual Meeting of the Hematology/Oncology Pharmacy Association; Abstract #PR6. June 14-16, 2007; Denver, Colorado. http://www.hoparx.org/documents/2007 programbook.pdf. Accessed November 2, 2010.
20. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219-227. [15538640]
21. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. New York: Oxford University Press; 2005.
22. Hayman J, Weeks J, Mauch P. Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy. Int J Radiat Oncol Biol Phys 1996;35: 827-841. [8690653]
23. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost- effectiveness analysis. J Clin Oncol 2000;18:72-79. [10623695]
24. Ramsey SD, Liu Z, Boer R, et al. Cost- effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2008;11:172-179. [18673353]
25. Hillner BE, Ingle JN, Chlebowski RT, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042- 4057. [12963702]
26. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guideline. J Clin Oncol 2006;24:3187-3205. [16682719]
27. National Cancer Institute. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Breast. http://seer.cancer.gov/statfacts/html/breast.html. Accessed May 16, 2010.
28. Tumeh JW, Moore SG, Shapiro R, Flowers CR. Practical approach for using Medicare data to estimate costs for cost- effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2005; 5:153-162. [19807571]
29. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641. [12885677]
30. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost- effectiveness analysis. J Clin Epidemiol 1992;45: 505-512. [1588356]
31. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality- adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342. [10929856]
32. Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin 2008;58:231-244. [18596196]
33. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-95. [16476830]
34. Braithwaite RS, Meltzer DO, King JT, Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356. [18362813]
35. National Institutes of Health Consensus Development Panel. 1997 Consensus Statement: Breast Cancer Screening for Women Ages 40-49. http://consensus.nih.gov/1997/1997BreastCancerScreening103html.htm. Accessed October 13, 2007.
36. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997;127:955-965. [9412300]
37. Shih YC, Han S, Cantor SB. Impact of generic drug entry on cost- effectiveness analysis. Med Decis Making 2005;25:71- 80. [15673583]
38. Roila F, Hesketh PJ, Herrstedt J; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapyinduced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-28. [16314401]
39. Grunberg SM, Ireland A. Epidemiology of chemotherapy-induced nausea and vomiting. Adv Studies Nurs 2005;3(1):9-15. http://www.jhasin.com/files/articlefiles/pdf/XASIN_3_1_p9_15.pdf. Accessed September 16, 2010.
40. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-408. [17004515]
41. Grunberg SM, Dugan M, Muss HB, Wood M, Burdette-Radoux S, Weisberg T. Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy. J Clin Oncol 2007;25(18S):9111.
42. U. S. Department of Labor. Bureau of Labor Statistics. Consumer Price Index. http://www.bls.gov/cpi/home.htm. Accessed May 16, 2010.
43. Department of Health and Human Services. Centers for Medicare & Medicaid Services. Medicare Program; Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2008 Rates. CMS-1533-P, pp 1070- 1073. http://www.cms.hhs.gov/AcuteInpatientPPS/downloads/CMS-1533-P.pdf. Accessed May 16, 2010.